Shares of Versartis Inc. (NASDAQ:VSAR) saw unusually-strong trading volume on Wednesday . Approximately 93,795 shares changed hands during trading, an increase of 6% from the previous session’s volume of 88,302 shares.The stock last traded at $12.76 and had previously closed at $13.12.

Several equities research analysts have commented on VSAR shares. Zacks Investment Research cut shares of Versartis from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th. Canaccord Genuity reissued a “buy” rating on shares of Versartis in a research report on Tuesday, May 10th. Credit Suisse Group AG reissued a “sell” rating and set a $9.00 price target on shares of Versartis in a research report on Friday, July 29th. Finally, Citigroup Inc. set a $23.00 price target on shares of Versartis and gave the stock a “buy” rating in a research report on Thursday, August 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $18.00.

The firm has a 50-day moving average of $11.81 and a 200-day moving average of $9.59. The stock’s market cap is $366.31 million.

Versartis (NASDAQ:VSAR) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.03. Equities research analysts predict that Versartis Inc. will post ($2.76) earnings per share for the current fiscal year.

In other Versartis news, CEO Jay Shepard sold 5,442 shares of the firm’s stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $12.88, for a total value of $70,092.96. Following the completion of the sale, the chief executive officer now directly owns 155,358 shares in the company, valued at $2,001,011.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.